These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33125750)

  • 1. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia.
    Roumier M; Le Burel S; Audia S; Chauchet A; Gousseff M; Hamidou M; Liferman F; Moulis G; Lioger B; Galicier L; Ebbo M; London J; Poutrel S; Terriou L; Zarrouk V; Michel M; Godeau B; Mahevas M
    Am J Hematol; 2021 Feb; 96(2):E43-E46. PubMed ID: 33125750
    [No Abstract]   [Full Text] [Related]  

  • 2. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
    DasGupta RK; Levine L; Wiczer T; Cataland S
    J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment.
    Ignatova AA; Demina IA; Ptushkin VV; Khaspekova SG; Shustova ON; Pankrashkina MM; Ryabykh AA; Obydennyi SI; Strelkova OS; Polokhov DM; Seregina EA; Poletaev AV; Ataullakhanov FI; Kireev II; Mazurov AV; Maschan AA; Novichkova GA; Panteleev MA
    Br J Haematol; 2019 Oct; 187(2):e38-e42. PubMed ID: 31422582
    [No Abstract]   [Full Text] [Related]  

  • 4. Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment.
    Tagariello G; Sartori R; Radossi P; Maschio N; Risato R; Stasi R
    Br J Haematol; 2012 Apr; 157(2):256-8. PubMed ID: 22111882
    [No Abstract]   [Full Text] [Related]  

  • 5. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia.
    Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S
    Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881
    [No Abstract]   [Full Text] [Related]  

  • 7. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.
    Janssens A; Tarantino M; Bird RJ; Mazzucconi MG; Boccia RV; Fernández MF; Kozak T; Steurer M; Boekhorst Pt; Dillingham K; Kreuzbauer G; Woodard P
    Acta Haematol; 2015; 134(4):215-28. PubMed ID: 26066765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
    Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
    J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 11. Romiplostim: an alternative treatment option besides rituximab for the management of steroid refractory idiopathic thrombocytopenic purpura.
    Kapoor S
    J Thromb Thrombolysis; 2009 May; 27(4):453. PubMed ID: 18438700
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
    Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
    J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K; Kambara N
    Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia.
    Álvarez-Román MT; Rivas Pollmar MI; Bernardino JI; Lozano ML; Martín-Salces M; Fernández-Bello I; Jiménez-Yuste V; Butta NV
    AIDS; 2016 Apr; 30(7):1141-2. PubMed ID: 27028144
    [No Abstract]   [Full Text] [Related]  

  • 17. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.
    Bussel JB; Wang X; Lopez A; Eisen M
    Hematology; 2016 May; 21(4):257-62. PubMed ID: 26251926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Kuter DJ; Arnold DM; Rodeghiero F; Janssens A; Selleslag D; Bird R; Newland A; Mayer J; Wang K; Olie R
    Am J Hematol; 2020 Jun; 95(6):643-651. PubMed ID: 32129511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 20. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.